The U.S. Food and Drug Administration has approved Opzelura cream 1.5 percent (ruxolitinib) for children ages 2 to 11 years ...

IMPACT-HTN, a novel initiative to modernize hypertension care, has been launched by Idorsia at Stanford Hypertension Center and Duke Heart Center.

The decision to broaden the antibody’s indication was based on clinical efficacy and safety data from six children.

The ACR recently issued the first formal international consensus guidance statement on diagnosing and managing VEXAS syndrome.

A new review highlights the anti-inflammatory potential of Hibiscus sabdariffa (roselle), synthesizing evidence from 25 studies published between 2019 and 2024. Most findings are from preclinical ...